CGT 研究的前景和技术发展的机会

CGT Research Outlook and Technology Growth Opportunities

出版日期: 2024年08月05日 | 出版商:

Frost & Sullivan | 英文 76 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

资本利得税状况评估

过去 10 年来，CGT 周围的环境发生了巨大变化。超过 80 种 CGT 产品在全球范围内上市，其中 34 种细胞和基因疗法仅在 2023 年就获得 FDA核准。不断增加的产品平臺和临床成功率正在推动对新技术平台开发、製造能力和扩展到新疾病领域的需求。

过去五年，专利格局、投资格局和临床试验空间持续成长和活跃。所有这三个领域都对资本利得税的成长做出了重大贡献，并显示出资本利得税未来的巨大潜力。 CGT领域主要分为三大类：细胞疗法、基因疗法和基因改造细胞疗法，这三者在过去几年中都取得了良好的进展。 CAR-T和CAR-NK等基因改造细胞疗法有许多临床计画正在进行中，预计在未来几年将具有较高的临床疗效。

除了血液学和肿瘤学之外，CGT 开发人员还在开拓糖尿病、心血管疾病和神经系统疾病等新疾病领域，这可能会推动对 CGT 的需求。

本报告涵盖了CGT的发展现状和趋势。展示出广泛采用新技术来提高 CGT 的协作环境将改变 CGT 开发和製造的端到端能力。

由于载体设计、细胞株製造、CGT 製造能力数位化以及端到端 CGT 开发中的人工智慧整合等技术的持续发展，专利活动处于高水准。创业投资新兴企业看到了未来几年资本利得税领域的巨大潜力，并正在支持新创公司和中型资本利得税开发商加速其管道建设。未来几年，获得监管部门核准的 CGT 数量预计将增加两倍，并将实施政策以增加患者的可及性。

最近促进创新的努力和研究加速器
CGT 研究和开发的全球趋势
CGT发展的新技术领域
载体的选择取决于适应症和转基因基因表现
病毒载体工程提升安全性和功能性
向量工程创新
从自体细胞疗法转变为同种异体细胞疗法的转变仍在继续
CGT 製造的新技术趋势
转向 CGT 製造的未来工厂
CGT 平台与生物製药公司最近为加速 CGT 开发而进行的引人注目的合作

CGT临床试验现状

基因治疗临床管线开发
基因改造细胞疗法的临床进展
干细胞治疗的临床管道开发

CGT 中的成长机会领域

成长机会1：扩大CDMO产能与能力
成长机会 2：技术授权合作伙伴关係
成长机会 2：技术授权合作伙伴关係
成长机会3：转向针对慢性病的CGT开发

附录

技术成熟度等级 (TRL)：解释

下一步

成长机会的好处和影响
下一步
下一步
免责声明

简介目录

Product Code: DAE6

CGT Landscape Assessment

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, and expansion to new disease areas.

Over the past five years, the patent landscape, investment landscape, and clinical trial segment have had consistent growth and activity. All three segments contribute extensively to the growth of CGTs and showcase the promising potential of CGTs for the future. The CGT landscape has three main categories of therapies: cell therapies, gene therapies, and gene-modified cell therapies, with all three progressing well over the past years. Gene-modified cell therapies, such as CAR-T and CAR-NK, have a higher number of clinical programs in the pipeline and are expected to have a high clinical impact in the coming years.

CGT developers are exploring new disease areas, apart from hematological conditions and oncology, to include diabetes, cardiovascular diseases, and neurological conditions, which will boost the demand for CGTs.

The report covers the developments and trends in the CGT landscape. A collaborative environment showing the high adoption of new technologies to improve CGTs will transform the end-to-end capabilities in CGT development and manufacturing.

Patent activity is high because of consistent developments in technology for vector design, cell line manufacturing, digitalization of CGT manufacturing capabilities, and AI integration across the end-to-end CGT development. Venture capital firms see huge potential in the CGT segment in the coming years and have been constant supporters in backing start-ups and mid-sized CGT developers to accelerate their pipelines. In the coming years, the number of CGTs receiving regulatory approvals is predicted to multiply by three fold, and policies will be put in place to increase patient accessibility.

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints
Macro to Micro Visioning and Implications
Snapshot of CGT Development
Global Growth of CGT Approvals
CGT R&D Outlook
Manufacturing Expansion: Catalysts for CGT Manufacturing

CGT Patent Analysis

CGT-Overall Patent Trends
IP Landscape Gene-modified Cell Therapies
Top Patent Applicants in Gene-modified Cell Therapies
IP Landscape-Gene Therapies
Top Patent Applicants in Gene Therapies
IP Landscape Stem Cell Therapies
Top Patent Applicants in Stem Cell Therapies
An Overview of the Patent Landscape in CGTs

CGT Investment Landscape

Investment Trends in the CGT Landscape
Investment Trends in the CGT Expansion of Manufacturing Units
Investments in CGT Technology Platforms
Growing Mergers and Acquisitions
Early-stage CGT Investment Trends by Venture Capitalists
GV, United States
SAMSARA BIOCAPITAL, United States
ARCH VENTURE PARTNERS, United States
OrbiMed, United States
ALEXANDRIA, United States
RA CAPITAL, United States

CGT Publication Trend

Publication Trends in CGT

R&D Outlook across the Value Chain

Recent Initiatives and Research Accelerators Driving Innovations
Global Trends in CGT R&D
Emerging Technology Areas in CGT Development
Choice of Vector Depends on Indication and Transgene Expression
Engineering Viral Vectors to Improve Safety and Functionality
Innovations in Vector Engineering
Growing Shift from Autologous to Allogeneic Cell Therapies
Emerging Technology Trends for CGT Manufacturing
Shift toward Factory of the Future for CGT Manufacturing
Notable Recent Collaborations between CGT Platforms and Biopharma Companies to Accelerate CGT Development